Uncategorized Archives - Page 36 of 142

WednesdayFeb 08, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth

Market analysts predict monoclonal antibodies (“mAbs”) will be the fastest-growing revenue segment of the biologics medicinal market through the end of the decade BiondVax Pharmaceuticals is focused on developing and commercializing novel mAb “biobetter” NanoAbs to meet underserved medical needs addressing large market disorders The company’s recent work with an inhaled nanosized antibody for COVID has shown exceptionally promising results, virtually preventing illness and eliminating the SARS-COV-2 virus in a hamster population With COVID as first target, the company’s pipeline aims to provide effective medical responses to other disorders such asthma, psoriasis, psoriatic arthritis, and macular degeneration Immunotherapeutic product innovator…

MondayFeb 06, 2023 11:15 am

MetAlert, Inc. (MLRT) – Developing New and Practical GPS Tracking and Other Health Tech Solutions for Real-World Caregivers and Businesses

MetAlert, a developer of personal protective medical equipment and supplies, owes much of its growth to acting on feedback from real-world caregivers who use its products for the monitoring and tracking of vulnerable patients This connection with caregivers has yielded advanced products such as the award-winning, multi-patented GPS SmartSole, Invisabelt, Take-Along Tracker, and Rover Tracker, among others Attention to consumers has also led to its line of hearing aids, such as its flagship Hear IQ 4 rechargeable, app-controlled hearing aid, and its RoomMate wall-mounted 3D sensors for looking after patients without intruding on their personal space MetAlert (OTC: MLRT), a…

MondayFeb 06, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company is developing nanosized antibodies (“NanoAbs”) addressing large market diseases underserved by current treatments, with its lead candidate targeting COVID-19 The FDA recently revoked the sole authorization of a COVID prophylactic, Evusheld, citing the inability of the monoclonal antibody cocktail to neutralize emerging subvariants of the Omicron variant BiondVax’s lead NanoAb candidate shows superior advantages to monoclonal antibodies, with the data gathered strengthening the value proposition of the COVID-19 NanoAb as a safe, efficacious, and convenient therapeutic and prophylactic drug The Food and Drug Administration…

ThursdayFeb 02, 2023 9:00 am

MetAlert, Inc. (MLRT) Patient Tracking Technology To Gain User Access in Sweden’s Cognitive Care Centers

GPS-enabled location device developer MetAlert provides geographical tracking technology that is discrete and functional through shoe inserts that provide data connectivity to cognitive patient caregivers MetAlert announced in January that it is expanding the reach of its SmartSole flagship product through an agreement with Sweden’s government that was established by distribution partner Posifon AB Government agencies across Europe and in the United States have recognized the importance of being able to monitor the whereabouts of patients with cognitive concerns MetAlert’s development team has improved the SmartSole with a battery capable of lasting up to five days, and the company plans…

MondayJan 30, 2023 11:15 am

MetAlert, Inc. (MLRT) Market for Self-actualized Wellness Grows

Wearable wellness technology innovator MetAlert is revitalizing its brand and increasing its product and services portfolio through M&A and other corporate developments designed to improve the company’s healthcare profile The mortality associated with chronic disease can be ameliorated with the use of wearable devices, along with other healthful practices, and the use of wearable wellness technology is expected to continue at an increasing pace More than 41 million people die of noncommunicable diseases (aka chronic illnesses) each year — 17 million of them before the age of 70, according to the World Health Organization MetAlert’s growing product slate is designed…

MondayJan 30, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study

BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers The study shows promising prophylactic results with hamsters receiving BiondVax’s inhaled NanoAb three hours before infection experiencing no significant weight loss over the six-day trial; follows previously reported data showing successful use of NanoAb as COVID-19 therapeutic First-in-human Phase 1/2a clinical trial is planned for later this year Focused on the development, manufacture, and commercialization of innovative NanoAb immunotherapeutic products, BiondVax Pharmaceuticals (NASDAQ: BVXV) recently announced additional…

ThursdayJan 26, 2023 9:45 am

MetAlert, Inc. (MLRT) Planned Acquisition of TrakTec LLC Adds Superior Radio Frequency-Based Tracking Technology to Portfolio of Location-Based Solutions

MetAlert recently announced the planned acquisition of TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications The acquisition is expected to add several products to MetAlert’s existing suite of products, one of which is an RFID and Bluetooth-enabled tracking technology called SafetyNet(R) The SafetyNet Tracking System comprises the SafetyNet Bracelets that patients wear, and a receiver-antenna combo used by police departments and first responders The Chelmsford Police Department in Massachusetts recently reported it had successfully located a missing senior citizen with dementia because of its participation in the SafetyNet program The department has, over time,…

ThursdayJan 26, 2023 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial

SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions Data collection from all study groups expected by April 2023 SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on…

TuesdayJan 24, 2023 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space

Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO With heart disease consistently being the leading cause of death in the United States (https://ibn.fm/kDLwz), companies such as HeartBeam (NASDAQ: BEAT) that are focusing on solutions are gaining both attention and support. As a cardiac technology company, HeartBeam is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution. HeartBeam’s efforts…

MondayJan 23, 2023 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19

Current monoclonal antibody therapies less effective against emerging COVID-19 variants BiondVax is developing an inhaled nanosized antibody (NanoAb) therapy for COVID-19 with human clinical Phase 1/2a results anticipated in 2023 The global monoclonal antibodies market was valued at $185.5 billion in 2021 and is projected to grow at a CAGR of 11.3% due to the rising prevalence of chronic diseases and demand for biologics The biologics market size was valued at $366.5 billion in 2021 and is expected to reach $719.94 billion by 2030 According to a new study, new COVID-19 subvariants have become dominant in recent months, rendering some…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth

MetAlert, Inc. (MLRT) – Developing New and Practical GPS Tracking and Other Health Tech Solutions for Real-World Caregivers and Businesses

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb

MetAlert, Inc. (MLRT) Patient Tracking Technology To Gain User Access in Sweden’s Cognitive Care Centers

MetAlert, Inc. (MLRT) Market for Self-actualized Wellness Grows

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study

MetAlert, Inc. (MLRT) Planned Acquisition of TrakTec LLC Adds Superior Radio Frequency-Based Tracking Technology to Portfolio of Location-Based Solutions

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial

HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search